Cost-effectiveness of eltrombopag (Revolade®) for the treatment of chronic immune thrombocytopenic purpura (ITP).
|30/07/2010||05/11/2010||Reimbursement not recommended.|
The review group do not recommend the reimbursement of eltrombopag under the High Tech Drug scheme.
|A new rapid review was commissioned by the HSE in December 2017|
|Rapid review commissioned||04/12/2017|
|Rapid review completed||16/04/2018|
|Rapid Review outcome||A full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with currently available therapies.|